Antiretroviral therapy and peripheral T cell apoptosis

Antiretroviral therapy and peripheral T cell apoptosis - ARTA

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON37267

Enrollment

Registered

2012-06-13

Start date

2012-07-13

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV Human immunodeficiency virus

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - subjects must be willing and able to provide written informed consent - Age >18 and 40 and 1 year - subjects must meet the following criteria per patient group: o *PI-group* (n=15): HAART must consist of a protease inhibitor (e.g. atazanavir, lopinavir, darunavir), boosted with ritonavir, in combination with backbone therapy consisting of tenefovir and emtricitabine but without any other antiretroviral medicine. o *NNRTI-group* (n=15): HAART must consist of a non-nucleoside reverse transcriptase inhibitor (efavirenz, nevirapine) in combination with backbone therapy consisting of tenofovir and emtricitabine without any other antiretroviral medicine.

Exclusion criteria

Exclusion criteria: - Detectable HIV-RNA within 6 months before inclusion - CD4-count

Design outcomes

Primary

Measure	Time frame
T cell apoptosis is measured by Annexin V and propidium idodide stainings.	—

Secondary

Measure	Time frame
Furthermore, caspase-activity will be evaluated as well as T cell phenotypes.	—

Countries

Netherlands

Outcome results